This Core serves two functions. The first is to provide a service to other TCORS investigators by carrying out the analysis of biofluid samples for their studies. The second is to develop new biomarkers of exposure that can be applied to the studies carried out by TCORS investigators, as well as to advance the field. Our laboratory is able to measure alkaloids and toxic substances in both tobacco products and in tobacco smoke. These measurements are needed for biomarker development and to interpret the biomarker data for distinguishing smokeless from smoked tobacco use. These measurements will include other substances in order to explore relationships between toxins and toxin precursors in tobacco and smoke with exposure determined using biomarkers. The improved exposure assessment measures that we expect to develop, and their application to studies carried out by the TCORS, could serve as models for future studies of the risks of new tobacco products and provide scientific basis for their regulation.

Public Health Relevance

The development and validation of biomarkers is a high priority issue for FDA regulation. Studies of tobacco product chemistry with biomarker analyses may provide information on which substances are associated with toxin exposure in humans. Precursors in smoking products that generate toxic substances might provide leads for reducing the toxicity of new products or be targets for regulation. We expect that our studies will result in improved methods for determining human exposure to toxic substances in tobacco and tobacco smoke.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA180890-02
Application #
8754525
Study Section
Special Emphasis Panel (ZRG1-BDCN-A)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
2
Fiscal Year
2014
Total Cost
$378,787
Indirect Cost
$138,649
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Halpern-Felsher, Bonnie; Kim, Hyoshin (2018) Measuring E-cigarette use, dependence, and perceptions: Important principles and considerations to advance tobacco regulatory science. Addict Behav 79:201-202
Nabavizadeh, Pooneh; Liu, Jiangtao; Havel, Christopher M et al. (2018) Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke. Tob Control 27:s13-s19
Kulik, Margarete C; Lisha, Nadra E; Glantz, Stanton A (2018) E-cigarettes Associated With Depressed Smoking Cessation: A Cross-sectional Study of 28 European Union Countries. Am J Prev Med 54:603-609
Glantz, Stanton A; Gardiner, Philip (2018) Local Movement to Ban Menthol Tobacco Products as a Result of Federal Inaction. JAMA Intern Med 178:711-713
Barrington-Trimis, Jessica L; Gibson, Laura A; Halpern-Felsher, Bonnie et al. (2018) Type of E-Cigarette Device Used Among Adolescents and Young Adults: Findings From a Pooled Analysis of Eight Studies of 2166 Vapers. Nicotine Tob Res 20:271-274
Glantz, Stanton A; Bareham, David W (2018) E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications. Annu Rev Public Health 39:215-235
Yao, Tingting; Sung, Hai-Yen; Wang, Yingning et al. (2018) Healthcare costs attributable to secondhand smoke exposure at home for U.S. adults. Prev Med 108:41-46
McKelvey, Karma; Baiocchi, Mike; Ramamurthi, Divya et al. (2018) Youth say ads for flavored e-liquids are for them. Addict Behav :
Moazed, Farzad; Chun, Lauren; Matthay, Michael A et al. (2018) Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Tob Control 27:s20-s25
St Helen, Gideon; Jacob Iii, Peyton; Nardone, Natalie et al. (2018) IQOS: examination of Philip Morris International's claim of reduced exposure. Tob Control 27:s30-s36

Showing the most recent 10 out of 101 publications